-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on TransCode Therapeutics, Lowers Price Target to $10

Benzinga·04/16/2025 11:38:24
Listen to the news
HC Wainwright & Co. analyst Emily Bodnar maintains TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and lowers the price target from $20 to $10.